TAP and MHC-I Expression Profiling for Immunotherapy Response

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer immunotherapies lack adequate predictive biomarkers for determining patient responsiveness, particularly for checkpoint-directed therapies, leading to variable response rates and limited effectiveness across different tumor types.

Innovation Solution

Assessment of the expression of the transporter associated with antigen processing (TAP) complex and major histocompatibility complex class I (MHC-I) components in biological samples using immunoenzymatic techniques and flow cytometry to stratify patients into likely responders and non-responders to MHC-I-dependent immunotherapeutic agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PD-L1 or TMB are used as predictive biomarkers, then treatment selection can be guided, but response rates remain variable and predictive value is insufficient

Engineering Contradiction:

Improvepredictive value of biomarkerVSAvoidaccuracy of response prediction

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent segments the antigen presentation machinery into distinct components (TAP1, TAP2, MHC class I) and evaluates each separately, allowing for more precise prediction of immune response. This segmentation enables identification of specific functional deficits that conventional bulk biomarkers like PD-L1 or TMB cannot detect.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent introduces TAP complex and MHC class I expression levels as intermediary biomarkers that mediate between tumor characteristics and immune response. These intermediary markers provide a more direct measure of antigen presentation capability, which is the actual functional mechanism underlying response to checkpoint inhibitors, rather than relying on indirect markers like PD-L1.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If checkpoint-directed therapies are administered to all patients, then treatment access is maximized, but ineffective treatments are administered to non-responders

Engineering Contradiction:

Improvenumber of patients treatedVSAvoidwasted treatment on non-responders

Core Design Contradiction:

ProductivityVSLoss of energy

Solution Approach 1:

The patent performs preliminary assessment of TAP and MHC class I expression before initiating checkpoint-directed therapy. This preliminary action identifies patients likely to respond to treatment, allowing for selective administration that avoids wasting treatment on non-responders while maintaining access for those who will benefit.

Inventive Principle:

Principle #10Preliminary action

3Measurement precision

If multiple biomarkers are evaluated, then predictive accuracy improves, but assay complexity and cost increase

Engineering Contradiction:

Improvepredictive accuracyVSAvoidassay complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent combines the evaluation of TAP complex and MHC class I expression into a unified assessment framework that can be performed using standard immunohistochemistry or flow cytometry platforms. This merging approach achieves high predictive accuracy without requiring entirely new, complex assay technologies, thereby limiting the increase in complexity and cost.

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Provides a method to identify subjects who may be responsive to MHC-I-dependent immunotherapeutic agents, enhancing the predictive value of treatment outcomes by identifying suitable candidates for checkpoint inhibitors and other therapies.

Implementation Method 1

Methodology Applied

Scientific EffectImmunoenzymatic detection: Enzyme

Implementation Method 2

Methodology Applied

Scientific EffectFlow cytometry:

Data Source

PatentUS20260016475A1Materials and methods for evaluation of antigen presentation machinery components and uses thereof

Publication Date: 2026.01.15 VENTANA MEDICAL SYSTEMS INC

AI summary

Disclosed herein are compositions, systems, and methods for identifying subjects who may be responsive to MHC-I-dependent immunotherapeutic agents based upon the expression of the components of the antigen presentation machinery and, in particular, the expression of the constituent elements of the transporter associated with antigen processing complex and the major histocompatibility complex class I.